Augmentation versus inhibition: Effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor

Journal of Immunology

Volumn 167, Issue 11, 2001, Pages 6669-6677

  Kjaergaard, J ^a   Peng, L ^a   Cohen, P A ^a   Drazba, J A ^a   Weinberg, A D ^a   Shu, S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; INTERLEUKIN 2; L SELECTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX40; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; EFFECTOR CELL; IMMUNOGENICITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR LOCALIZATION;

EID: 0035576267     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.11.6669     Document Type: Article

References (53)

1. Gene therapy: Current status and future prospects
2. Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment
3. Rejection of B 16 melanoma induced by expression of a transfected major histocompatibility complex class I gene
4. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
5. Adoptive T-cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
6. Tumor-draining lymph nodes as a source for generating therapeutic immune cells
7. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
8. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report
9. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
10. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human IL-2: Correlation with clonal IL-2 receptor expression
11. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy
12. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: Culture requirements and characterization of immunologic specificity
13. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy
14. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells
15. Treatment of subcutaneous tumor with adoptively transferred T cells
16. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes
17. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
18. + T cells with broad antitumor efficacy are naturally sensitized during tumor progression
19. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2
20. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells
21. Unique characteristics associated with systemic adoptive immunotherapy of experimental intracerebral tumors
22. Divergent effects of 4-IBB antibodies on antitumor immunity and on tumor-reactive T-cell generation
23. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth
24. Engagement of the OX-40 receptor in vivo enhances antitumor immunity
25. Adoptive immunotherapy of newly induced murine sarcomas
26. The selection and characterization of an invasive variant of the B16 melanoma
27. Studies on the chemotherapy of experimental brain tumors: Development of an experimental model
28. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for OX40 ligand
29. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression
30. Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells
31. Molecular characterization of murine and human OX40/OX40 ligand systems: Identification of a human OX40 ligand as the HTLV-1-regulated protein gp34
32. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy
33. New fluorescent dyes for lymphocyte migration studies: Analysis by flow cytometry and fluorescence microscopy
34. Calcein: A novel marker for lymphocytes which enter lymph nodes
35. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory
36. + T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness
37. + T cell- and IL-2-dependent mechanism
38. Antagonistic effects of systemic interleukin 2 on immune T cell-mediated graft-versus-leukemia reactivity
39. Local versus systemic interleukin 2: Tumor formation by wildtype and B7.1 positive murine melanoma cells
40. The first subcomponent of complement, Clq, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-I by human umbilical vein endothelial cells
41. Clonal expansion versus functional clonal inactivation: A costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy
42. CD28/B7 system of T cell costimulation
43. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity
44. The murine antitumor immune response and its therapeutic manipulation
45. Effects of ionizing radiation on the blood brain barrier permeability to pharmacologically active substances
46. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
47. Lymphocyte homing and homeostasis
48. Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier
49. The effect of intravenous interleukin-2 on brain water content
50. + T cells
51. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion
52. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion
53. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators